

**FDA Staff Manual Guides, Volume I - Organizations and Functions**

**Department of Health and Human Services**

**Food and Drug Administration**

**Center for Drug Evaluation and Research**

**Office of New Drugs**

**Office of Oncologic Diseases**

**Division of Hematologic Malignancies II**

Effective Date: September 25, 2019

**1. Division of Hematologic Malignancies II (DCDGFG).**

- A. Reviews Investigational New Drug applications and requests for claimed investigational exemption regulated by this Division and decides on appropriate action, including approval or disapproval of research plans and protocols, modifications, and restrictions. Develops policies and procedures pertinent to particular aspects of drug and biologics investigations.
- B. Evaluates New Drug Applications (NDAs) and Biological License Applications (BLAs) for safety and effectiveness and formulates decisions or recommendations regarding approvability in accord with applicable delegations of authority. Also evaluates supplements that propose changes in the conditions upon which NDA/BLA approvals are based. Develops policies and procedures applicable to the review and evaluation of hematologic malignancy drugs and biologics.
- C. Evaluates adequacy of information in proposed labeling for hematologic malignancy products.
- D. Evaluates and takes appropriate action on recommendations concerning withdrawal of approval of NDAs and BLAs for hematologic malignancy drugs and biologics.
- E. Develops, in coordination with other Food and Drug Administration (FDA) components, guidance for staff, sponsor and the public that describes the FDA's interpretation of or policy on regulatory issues that involve the hematologic

malignancy products. Also participates in FDA sponsored consumer and professional educational programs on drug standards.

- F. Performs medical and scientific evaluations of submissions on generic drugs, drugs under monograph, and Over-the-Counter drug products regulated by other offices in the Center, as applicable.

## **2. Authority and Effective Date.**

The functional statements for the Division of Hematologic Malignancies II were approved by the Secretary of Health and Human Services on September 25, 2019.

**Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of New Drugs  
Office of Oncologic Diseases  
Division of Hematologic Malignancies II**

Division of  
Hematologic Malignancies II

(DCDGF)

---

Staff Manual Guide 1263.80  
Organizations and Functions  
Effective Date: September 25, 2019

The following is the Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of Oncologic Disease, Division of Hematologic Malignancies II organization structure depicting all the organizational structures reporting to the Director.

Division of Hematologic Malignancies II (DCDGFG).